Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00092573
Recruitment Status : Completed
First Posted : September 28, 2004
Last Update Posted : February 28, 2017
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
The purpose of this study is to assess the cholesterol lowering safety and effectiveness of two investigational drugs in patients with mixed hyperlipidemia (high cholesterol and high triglycerides).

Condition or disease Intervention/treatment Phase
Hypercholesterolemia Hypertriglyceridemia Drug: MK0653, ezetimibe Drug: Comparator: fenofibrate monotherapy Phase 3

Detailed Description:
The duration of treatment is 48 weeks.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 576 participants
Primary Purpose: Treatment
Official Title: Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia
Study Start Date : April 2003
Primary Completion Date : November 2004
Study Completion Date : November 2004

Primary Outcome Measures :
  1. Tolerability

Secondary Outcome Measures :
  1. Plasma LDL-C, HDL-C and triglycerides after 12 weeks.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • High cholesterol and high triglycerides

Exclusion Criteria:

  • Patient has a condition which, in the opinion of the investigator, might pose a risk to the patient, interfere with participation in the study, or does not meet the additional criteria as required by the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00092573

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.

Study Data/Documents: CSR Snyopsis  This link exits the site

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00092573     History of Changes
Other Study ID Numbers: 0653-036 Extension
First Posted: September 28, 2004    Key Record Dates
Last Update Posted: February 28, 2017
Last Verified: February 2017

Keywords provided by Merck Sharp & Dohme Corp.:
Mixed hyperlipidemia (high cholesterol and high triglycerides)

Additional relevant MeSH terms:
Hyperlipidemia, Familial Combined
Hyperlipoproteinemia Type V
Lipid Metabolism Disorders
Metabolic Diseases
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents